Relmada Therapeutics, Inc.
RLMD
$0.627
$0.0172.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 44.47% | 19.56% | 25.86% | 1.25% | 29.78% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -51.73% | -47.97% | -26.58% | -37.43% | -39.66% |
| Change in Net Operating Assets | 100.95% | -895.25% | -46.73% | -48.42% | -1,288.53% |
| Cash from Operations | 51.73% | -38.59% | 14.15% | -43.21% | 0.08% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -52.35% | 52.70% | 46.56% | 318.18% | 1,316.84% |
| Cash from Investing | -52.35% | 52.70% | 46.56% | 318.18% | 1,316.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -75.13% | -- | -- |
| Cash from Financing | -- | -- | -75.13% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -72.90% | 1.79% | 191.03% | 92.25% | 105.21% |